Cargando…
Immunotherapy progress and clinical strategy of unresectable locally advanced non-small cell lung cancer
Non-small cell lung cancer negative for actionable molecular markers entered the splendid era of immunotherapy. This review aims to provide an evidence-based summary for immunotherapy for unresectable locally advanced non-small cell lung cancer, and references for clinical strategies of immunotherap...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9945126/ https://www.ncbi.nlm.nih.gov/pubmed/36845690 http://dx.doi.org/10.3389/fonc.2023.1022042 |
_version_ | 1784892072682061824 |
---|---|
author | Zhang, Xiaofei Zhang, Jianguo Liu, Peiyi Wang, Juan Zhao, Kuaile Zhu, Zhengfei Gu, Kangsheng Zhao, Weixin |
author_facet | Zhang, Xiaofei Zhang, Jianguo Liu, Peiyi Wang, Juan Zhao, Kuaile Zhu, Zhengfei Gu, Kangsheng Zhao, Weixin |
author_sort | Zhang, Xiaofei |
collection | PubMed |
description | Non-small cell lung cancer negative for actionable molecular markers entered the splendid era of immunotherapy. This review aims to provide an evidence-based summary for immunotherapy for unresectable locally advanced non-small cell lung cancer, and references for clinical strategies of immunotherapy. Through literature review, the standard treatment for unresectable locally advanced non-small cell lung cancer should be radical concurrent radiotherapy and chemotherapy followed by consolidation immunotherapy. However, the efficacy of concurrent radiotherapy, chemotherapy combined with immunotherapy has not been improved, and its safety should be further validated. It is believed that induction immunotherapy plus concurrent radiotherapy and chemotherapy plus consolidation immunotherapy is promising. In clinical practice, the delineation of radiotherapy target should be relatively small. Pemetrexed combined with PD-1 inhibitor induces the strongest immunogenicity in chemotherapy, which is suggested by preclinical pathway study. Although there is no significant difference between PD1 and PD1 for effect, PD-L1 inhibitor is better in the combination treatment of radiotherapy which presents significantly less adverse events. |
format | Online Article Text |
id | pubmed-9945126 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-99451262023-02-23 Immunotherapy progress and clinical strategy of unresectable locally advanced non-small cell lung cancer Zhang, Xiaofei Zhang, Jianguo Liu, Peiyi Wang, Juan Zhao, Kuaile Zhu, Zhengfei Gu, Kangsheng Zhao, Weixin Front Oncol Oncology Non-small cell lung cancer negative for actionable molecular markers entered the splendid era of immunotherapy. This review aims to provide an evidence-based summary for immunotherapy for unresectable locally advanced non-small cell lung cancer, and references for clinical strategies of immunotherapy. Through literature review, the standard treatment for unresectable locally advanced non-small cell lung cancer should be radical concurrent radiotherapy and chemotherapy followed by consolidation immunotherapy. However, the efficacy of concurrent radiotherapy, chemotherapy combined with immunotherapy has not been improved, and its safety should be further validated. It is believed that induction immunotherapy plus concurrent radiotherapy and chemotherapy plus consolidation immunotherapy is promising. In clinical practice, the delineation of radiotherapy target should be relatively small. Pemetrexed combined with PD-1 inhibitor induces the strongest immunogenicity in chemotherapy, which is suggested by preclinical pathway study. Although there is no significant difference between PD1 and PD1 for effect, PD-L1 inhibitor is better in the combination treatment of radiotherapy which presents significantly less adverse events. Frontiers Media S.A. 2023-02-08 /pmc/articles/PMC9945126/ /pubmed/36845690 http://dx.doi.org/10.3389/fonc.2023.1022042 Text en Copyright © 2023 Zhang, Zhang, Liu, Wang, Zhao, Zhu, Gu and Zhao https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Zhang, Xiaofei Zhang, Jianguo Liu, Peiyi Wang, Juan Zhao, Kuaile Zhu, Zhengfei Gu, Kangsheng Zhao, Weixin Immunotherapy progress and clinical strategy of unresectable locally advanced non-small cell lung cancer |
title | Immunotherapy progress and clinical strategy of unresectable locally advanced non-small cell lung cancer |
title_full | Immunotherapy progress and clinical strategy of unresectable locally advanced non-small cell lung cancer |
title_fullStr | Immunotherapy progress and clinical strategy of unresectable locally advanced non-small cell lung cancer |
title_full_unstemmed | Immunotherapy progress and clinical strategy of unresectable locally advanced non-small cell lung cancer |
title_short | Immunotherapy progress and clinical strategy of unresectable locally advanced non-small cell lung cancer |
title_sort | immunotherapy progress and clinical strategy of unresectable locally advanced non-small cell lung cancer |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9945126/ https://www.ncbi.nlm.nih.gov/pubmed/36845690 http://dx.doi.org/10.3389/fonc.2023.1022042 |
work_keys_str_mv | AT zhangxiaofei immunotherapyprogressandclinicalstrategyofunresectablelocallyadvancednonsmallcelllungcancer AT zhangjianguo immunotherapyprogressandclinicalstrategyofunresectablelocallyadvancednonsmallcelllungcancer AT liupeiyi immunotherapyprogressandclinicalstrategyofunresectablelocallyadvancednonsmallcelllungcancer AT wangjuan immunotherapyprogressandclinicalstrategyofunresectablelocallyadvancednonsmallcelllungcancer AT zhaokuaile immunotherapyprogressandclinicalstrategyofunresectablelocallyadvancednonsmallcelllungcancer AT zhuzhengfei immunotherapyprogressandclinicalstrategyofunresectablelocallyadvancednonsmallcelllungcancer AT gukangsheng immunotherapyprogressandclinicalstrategyofunresectablelocallyadvancednonsmallcelllungcancer AT zhaoweixin immunotherapyprogressandclinicalstrategyofunresectablelocallyadvancednonsmallcelllungcancer |